Drrx stock zacks

By Grant Zeng, CFA NASDAQ:DRRX On August 1, Durect (NASDAQ:DRRX) announced its financial results for the second quarter of 2016 ended June 30. Total revenues for 2Q16 were $3.2 million, compared to $4.4 million for the same period of last year, a decrease of 28.8%. RD expenses for 2Q16 were $7.9 million, compared to $5.6 million for 2Q15. DRRX DURECT Corporation Stock Quote - FINVIZ.com

MARK | Complete Remark Holdings Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview. Mar. 30, 2020 at 12:30 p.m. ET on Zacks.com. Zacks: Analysts Set $4.09 Price Target for DURECT Co ... DURECT Co. (NASDAQ:DRRX) has earned an average broker rating score of 1.67 (Buy) from the three analysts that provide coverage for the company, Zacks Investment Research reports. One research analyst has rated the stock with a hold rating and two have assigned a strong buy rating to the company. Brokerages have set a 1-year consensus […] Zacks: Analysts Anticipate DURECT Co. (NASDAQ:DRRX) Will ... Brokerages expect that DURECT Co. (NASDAQ:DRRX) will report $10.38 million in sales for the current fiscal quarter, Zacks reports. Three analysts have issued estimates for DURECT’s earnings. The Durect: 4Q Earnings Snapshot - AP NEWS

Durect: 4Q Earnings Snapshot - AP NEWS

3 Jan 2020 ​Novan NOVN Incyte INCY Durect DRRX shares fall on disappointing data 3 months ago Zacks.com featured highlights include: HP, Party City, AbbVie, The logic is simple — a stock's current market price does not justify  DRRX | Complete Durect Corp. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview. Many of the stocks listed here are easily subjected to manipulation DRRX (T /$3) Durect Corp. technology right now is in COPD (Cronic Obstructive Pulmonary Disease). http://ir.pulmatrix.com/Zacks-Initiates-on-Pulmatrix- NASDAQ-PULM Implied Volatility Surging for KemPharm (KMPH) Stock Options - www.zacks.com. 2019-05-15 $ 1.2 (-1.64%). 7:00pm. KemPharm Reports First Quarter 2019  IB does not accept short sale orders for US stocks that are not eligible for DTC continuous net CZA, USD, INVESCO ZACKS MID-CAP ETF, Log In to Check Availability DRRX, USD, DURECT CORPORATION, Log In to Check Availability. 4 Mar 2015 Amarantus picked up eltoprazine in January 2014 for $100,000 in cash and $500,000 in stock. Amarantus recently paid another $500,000 in  Morningstar has also ventured into research reports for stocks, bonds, annuities, and The U.S. stock fund method uses the same ranking system as Zacks' 

4 Mar 2015 Amarantus picked up eltoprazine in January 2014 for $100,000 in cash and $500,000 in stock. Amarantus recently paid another $500,000 in 

After-Hours Earnings Report for March 14, 2017 : HTHT ... This value represents a 40.00% decrease compared to the same quarter last year. Zacks Investment Research reports that the 2016 Price to Earnings ratio for DRRX is -3.88 vs. an industry ratio of 5.60. Durect Corp DRRX - Quotes, Financials, News, Charts and ... Durect Corp DRRX Overview. About Durect Corp Analysts' recommendations provided by ZACKS Investment Research, Inc. Analysts' recommendations are for informational purposes only. DRRX | Durect Corp Financial Vitals | US News Best Stocks Financial summary and company information for Durect Corp DRRX Analysts' recommendations provided by ZACKS Investment There's seemingly a dramatic gulf between economic numbers and … Durect: 4Q Earnings Snapshot | Business | newsadvance.com

IB does not accept short sale orders for US stocks that are not eligible for DTC continuous net CZA, USD, INVESCO ZACKS MID-CAP ETF, Log In to Check Availability DRRX, USD, DURECT CORPORATION, Log In to Check Availability.

Zacks Small-Cap Research Sponsored Impartial - Comprehensive scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 June 27, 2019 Brian Marckx, CFA bmarckx@zacks.com Ph (312) 265-9474 Favorable FDA Decision on POSIMIR Would Likely Mean Significant Upside to Our Model We value DRRX using sum-of-the-parts, with most of the value WHATS NEW - s1.q4cdn.com

Analysts Expect DURECT Co. (NASDAQ:DRRX) to Announce -$0 ...

DRRX DURECT Corporation daily Stock Chart Opportunities Make DRRX Particularly Attractive at Current Valuation Zacks Small Cap Research. Aug-01- 19  According to Zacks Investment Research, based on 3 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.04. The reported EPS for the same   Researching DURECT (NASDAQ:DRRX) stock? View DRRX's stock price, price target, earnings, financials, forecast, insider trades, news, and SEC filings at  Market Data and Calendars. Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables,  Find the latest DURECT Corporation (DRRX) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and  

DURECT - Stock Price History | DRRX | MacroTrends